Abstract：
OBJECTIVE: Conducting a scoping review (SR) to assess scientific evidence for topical simvastatin\'s impact on alveolar bone regeneration and determine its level of support for clinical applications.
METHODS: This SR followed the PRISMA-ScR and OSF registries protocol; systematic searching was conducted on MEDLINE/PubMed, Cochrane, Embase, Scopus, Web of Science, and LILACS, to identify relevant articles until June 2023. Inclusion criteria covered clinical trials, case series, prospective and retrospective studies, along with in vivo investigations, involving participants of any sex and age.
RESULTS: Out of 1312 identified studies, 20 (9 in vivo, 11 RCTs) met inclusion criteria. RCTs focused on third molar extraction, in vivo on mandibular incisor surgery. The majority of RCTs employed a collagen sponge and a simvastatin concentration of 10mg; conversely, most in vivo studies favored polylactide-co-glycolide and a 2 mg simvastatin concentration. RCTs had 3-month follow-ups; in vivo, studies extended to 8 weeks. Seven RCTs assessed pain outcomes, simvastatin did not significantly affect pain in six studies. Among four RCTs on postoperative swelling, only two observed a significant increase in the simvastatin group. In general, positive bone formation and the absence of adverse effects directly linked to topical simvastatin were observed across the study models.
CONCLUSIONS: Intra-alveolar simvastatin post-tooth extraction has been to be shown to be effective and safe for preserving alveolar bone, with varied concentrations and carriers, with no significant adverse effects.
CONCLUSIONS: This review provides critical insights into the effects of simvastatin on alveolar bone regeneration, informing potential benefits and possible challenges associated with its post-extraction application. OSF REGISTRY PROTOCOL: osf.io/q3bnf.
METHODS: This SR followed the PRISMA-ScR and OSF registries protocol; systematic searching was conducted on MEDLINE/PubMed, Cochrane, Embase, Scopus, Web of Science, and LILACS, to identify relevant articles until June 2023. Inclusion criteria covered clinical trials, case series, prospective and retrospective studies, along with in vivo investigations, involving participants of any sex and age.
RESULTS: Out of 1312 identified studies, 20 (9 in vivo, 11 RCTs) met inclusion criteria. RCTs focused on third molar extraction, in vivo on mandibular incisor surgery. The majority of RCTs employed a collagen sponge and a simvastatin concentration of 10mg; conversely, most in vivo studies favored polylactide-co-glycolide and a 2 mg simvastatin concentration. RCTs had 3-month follow-ups; in vivo, studies extended to 8 weeks. Seven RCTs assessed pain outcomes, simvastatin did not significantly affect pain in six studies. Among four RCTs on postoperative swelling, only two observed a significant increase in the simvastatin group. In general, positive bone formation and the absence of adverse effects directly linked to topical simvastatin were observed across the study models.
CONCLUSIONS: Intra-alveolar simvastatin post-tooth extraction has been to be shown to be effective and safe for preserving alveolar bone, with varied concentrations and carriers, with no significant adverse effects.
CONCLUSIONS: This review provides critical insights into the effects of simvastatin on alveolar bone regeneration, informing potential benefits and possible challenges associated with its post-extraction application. OSF REGISTRY PROTOCOL: osf.io/q3bnf.
摘要：
目的：进行范围审查（SR），以评估局部辛伐他汀对牙槽骨再生影响的科学证据，并确定其对临床应用的支持水平。
方法：此SR遵循PRISMA-ScR和OSF注册协议；在MEDLINE/PubMed上进行了系统搜索，科克伦,Embase,Scopus,WebofScience,和LILACS,在2023年6月之前确定相关文章。纳入标准涵盖临床试验，案例系列,前瞻性和回顾性研究，随着体内研究，涉及任何性别和年龄的参与者。
结果：在1312项确定的研究中，20（体内9，11项随机对照试验)符合纳入标准。RCT专注于第三磨牙的提取，下颌切牙手术的活体研究。大多数随机对照试验采用胶原蛋白海绵和辛伐他汀浓度为10mg；相反，大多数体内研究支持聚丙交酯-共-乙交酯和2mg辛伐他汀浓度。随机对照试验有3个月的随访；在体内，研究延长至8周。七个RCT评估疼痛结果，在6项研究中,辛伐他汀对疼痛无显著影响.在关于术后肿胀的四项随机对照试验中，在辛伐他汀组中只有两个观察到显着增加。总的来说,在研究模型中观察到阳性骨形成和不存在与局部辛伐他汀直接相关的不良反应.
结论：牙槽内辛伐他汀拔牙后已被证明对保留牙槽骨有效且安全，具有不同的浓度和载体，无明显不良反应。
结论：这篇综述为辛伐他汀对牙槽骨再生的影响提供了重要的见解，告知与其提取后应用相关的潜在好处和可能的挑战。OSF注册协议：osf.io/q3bnf。
方法：此SR遵循PRISMA-ScR和OSF注册协议；在MEDLINE/PubMed上进行了系统搜索，科克伦,Embase,Scopus,WebofScience,和LILACS,在2023年6月之前确定相关文章。纳入标准涵盖临床试验，案例系列,前瞻性和回顾性研究，随着体内研究，涉及任何性别和年龄的参与者。
结果：在1312项确定的研究中，20（体内9，11项随机对照试验)符合纳入标准。RCT专注于第三磨牙的提取，下颌切牙手术的活体研究。大多数随机对照试验采用胶原蛋白海绵和辛伐他汀浓度为10mg；相反，大多数体内研究支持聚丙交酯-共-乙交酯和2mg辛伐他汀浓度。随机对照试验有3个月的随访；在体内，研究延长至8周。七个RCT评估疼痛结果，在6项研究中,辛伐他汀对疼痛无显著影响.在关于术后肿胀的四项随机对照试验中，在辛伐他汀组中只有两个观察到显着增加。总的来说,在研究模型中观察到阳性骨形成和不存在与局部辛伐他汀直接相关的不良反应.
结论：牙槽内辛伐他汀拔牙后已被证明对保留牙槽骨有效且安全，具有不同的浓度和载体，无明显不良反应。
结论：这篇综述为辛伐他汀对牙槽骨再生的影响提供了重要的见解，告知与其提取后应用相关的潜在好处和可能的挑战。OSF注册协议：osf.io/q3bnf。
